Tirzepatide maximum tolerated dose leads weight reduction ranking in obesity network meta-analysis
New analysis shows weight loss drugs work best for adults with obesity without diabetes
This systematic review and network meta-analysis of 14,059 adults with obesity without diabetes ranked GLP-1 receptor agonists and a dual ag…
A large review of many studies found that specific injectable medicines help adults lose weight. Tirzepatide worked best, but all options re…
GLP-1 agonists show short-term metabolic benefit in PCOS but reproductive effects remain uncertain
Doctors suggest GLP-1 drugs help weight but need careful planning before pregnancy in PCOS
A meta-analysis of GLP-1 receptor agonists in PCOS found relatively robust support for short-term metabolic benefit, but reproductive outcom…
New analysis shows GLP-1 drugs help with weight loss for PCOS patients. However, doctors are unsure if these drugs improve fertility and nee…
GLP-1 receptor agonists show no increased ocular disorder risk in type 2 diabetes meta-analysis
New analysis shows GLP-1 drugs do not raise eye disease risk for diabetes patients
This systematic review and meta-analysis of 28 observational studies found that GLP-1 receptor agonists did not increase the risk of NAION, …
A large review of 28 studies found that diabetes drugs called GLP-1 receptor agonists do not increase the risk of eye problems like glaucoma…
GLP-1RAs show lower risk of serious liver events compared with DPP-4 inhibitors in adults with type 2 diabetes
GLP-1 drugs may lower serious liver risks compared to DPP-4 inhibitors in type 2 diabetes
This systematic review and exploratory meta-analysis evaluated incident cirrhosis or composite serious liver events among adults with type 2…
A new analysis suggests GLP-1 receptor agonists might reduce serious liver events compared to DPP-4 inhibitors for adults with type 2 diabet…
GLP-1 receptor agonists reduce major adverse limb events with HR 0.59 in PAD
New analysis shows GLP-1 drugs cut stroke risk for people with leg artery disease
This systematic review and meta-analysis of over 240,000 adults with peripheral artery disease found that GLP-1 receptor agonists significan…
A large review of real-world data found GLP-1 drugs significantly reduce stroke and heart attack risk in adults with peripheral artery disea…
Real-time CGM improved HbA1c versus SMBG in adults with type 2 diabetes on basal insulin and modern therapies
Real-time glucose monitoring improves blood sugar control in type 2 diabetes
This randomised controlled trial compared real-time continuous glucose monitoring against standard self-monitoring of blood glucose in adult…
A new trial shows continuous glucose monitoring helps lower blood sugar levels better than standard finger-prick testing for adults with typ…
Bariatric surgery yields greater long-term weight loss than GLP-1 receptor agonists in adults with obesity
Bariatric surgery leads to more weight loss than GLP-1 drugs over one year
This meta-analysis compared bariatric surgery against GLP-1 receptor agonists in adults with obesity. While weight loss differences were not…
A large analysis of 20,594 adults found bariatric surgery caused greater weight loss than GLP-1 drugs after one year, with benefits growing …
Preoperative GLP-1 agonists yield moderate weight loss before bariatric surgery, meta-analysis finds
GLP-1 drugs before weight loss surgery: modest benefit, no extra risk
This meta-analysis of 5461 patients found that preoperative GLP-1 receptor agonist use led to moderate weight reduction (SMD 0.4, 4.87 kg vs…
Taking GLP-1 drugs before bariatric surgery helps drop a few extra pounds but doesn't boost long-term weight loss or raise complication risk…
GLP-1 receptor agonists show potential benefits for metabolic dysfunction-associated steatotic liver disease with acceptable safety
Review shows GLP-1 drugs may help fatty liver disease
This umbrella review evaluated twenty-three meta-analyses and systematic reviews regarding GLP-1 receptor agonists in patients with metaboli…
A review of many studies suggests GLP-1 receptor agonists may improve fatty liver disease, but the evidence is still early and needs stronge…
Genetic analysis links GLP-1 agonism to pancreatitis risk and sarcopenia in large cohorts
Genetic data link GLP-1 drugs to pancreatitis and muscle loss risks
A Mendelian randomization study of over one million participants suggests GLP-1 receptor agonists causally reduce diabetes risk but may incr…
Genetic analysis suggests GLP-1 receptor agonists may increase pancreatitis risk and muscle loss, while lowering blood sugar and diabetes ri…
Narrative review examines metabolic syndrome and novel agents in kidney transplant recipients
Kidney transplant patients face high metabolic risks and rejection
This narrative review addresses antibody-mediated rejection and metabolic syndrome in kidney transplantation recipients. The authors note th…
About half of kidney transplant recipients develop metabolic problems within a year, while antibody-mediated rejection remains a major cause…
Meta-analysis of Mendelian randomization suggests GLP-1 receptor agonism lowers vascular dementia risk
Genetic data suggests GLP-1 drugs may lower vascular dementia risk
This meta-analysis of Mendelian randomization studies evaluated the association between GLP-1 receptor agonism and dementia risk using genet…
New genetic evidence hints that GLP-1 receptor agonists might lower the risk of vascular dementia, but results for Alzheimer's disease remai…